Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 3 | Antimicrobial Resistance & Infection Control

Fig. 3

From: Impact of the COVID-19 pandemic on extended-spectrum β-lactamase producing Escherichia coli in urinary tract and blood stream infections: results from a nationwide surveillance network, Finland, 2018 to 2022

Fig. 3

The quarterly analysis of the proportions of extended-spectrum β-lactamase-producing Escherichia coli in (A) urine and (C) blood E. coli isolates and the number of urine (B) and blood (D) E. coli isolates tested, Finland, 2018–2022. ESBL+: extended-spectrum β-lactamase-producing Escherichia coli, Q1-Q4: quarter 1–4

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us